Irlab: Initial comment – Mesdopetam misses primary endpoint in PD-LID phase IIb trial - Redeye

Redeye is disappointed to learn that Irlab’s drug candidate mesdopetam, that targets levodopa induced dyskinesia, failed to show a statistically significant treatment effect in the primary endpoint in a phase IIb trial, although an effect was shown in a secondary endpoint. We give our initial comment.

Länk till analysen i sin helhet: https://www.redeye.se/research/871280/irlab-initial-comment-mesdopetam-misses-primary-endpoint-in-pd-lid-phase-iib-trial?utm_source=finwire&utm_medium=RSS